The PGS test and the FDA’s subsequent order of 23andMe to cease marketing the test to consumers has stirred controversy, and brought focus to an issue labs may have to face sooner rather than later: What role should labs play in whole-genome sequencing performed for health screening?

More news on FDA 23 and Me ( Click on this link for Dec 2014 news below):

Last week, it was announced that the Google-associated home DNA screening kit, 23andMe will be launched in the UK. In the US, however, 23andMe remains unavailable – a Food and Drug Administration order issued in November 2013 instructed the company to desist from marketing their eponymous genomics kit in the US. We investigate the issue.

One comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.